First FDA-Approved Treatment for MacTel Performed

First FDA-approved treatment for MacTel performed

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.

First FDA-approved MacTel treatment performed

Neurotech Pharmaceuticals performs the first ENCELTO procedure.

First FDA-Approved Treatment for MacTel Performed

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure for its encapsulated cell-based gene therapy Encelto (revakinagene taroretcel-lwey). Encelto was approved in March 2025 as the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). “This is a huge milestone for people living with MacTel. For the first time, there is an FDA-approved treatment …